Related Experiment Video
Updated: Dec 9, 2025
10:09
Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence
Published on: January 7, 2019
8.5K
Delta-like Factor 1 as a Possible Therapeutic Target for Sarcomas
Han-Soo Kim1,2, Sun Hee Ahn1, Ha Jeong Kim1
1Department of Orthopedic Surgery, Seoul National University Hospital, Seoul, Korea.
Clinics in Orthopedic Surgery
|September 9, 2020
Summary
The delta-like factor 1 (DLK1) gene promotes sarcoma growth and invasion. Inhibiting DLK1 showed anti-cancer effects, suggesting DLK1 as a potential therapeutic target for sarcoma treatment.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Research
Background:
- Cancer stem cells (CSCs) possess self-renewal and tumorigenic capabilities.
- Sarcomas are a diverse group of cancers originating from connective tissues.
Purpose of the Study:
- To investigate the role of delta-like factor 1 (DLK1) in sarcoma development and progression.
- To explore DLK1 as a potential therapeutic target in sarcoma.
Main Methods:
- Examined DLK1 mRNA expression in 13 sarcoma cell lines.
- Isolated and analyzed CSCs using fluorescence-activated cell sorting (FACS) and sphere-forming assays.
- Assessed the impact of DLK1 inhibition via short interfering RNA (siRNA) on sarcoma cell proliferation and invasion.
Main Results:
- High DLK1 mRNA expression was detected across all sarcoma cell lines.
- CSCs isolated from DLK1-overexpressing sarcomas showed lower DLK1 expression than wild-type cells.
- DLK1 inhibition suppressed proliferation and invasion in multiple sarcoma cell lines, including CSCs, and regulated liposarcoma invasiveness.
Conclusions:
- The DLK1 gene drives tumorigenesis and contributes to the invasive mechanisms in various sarcomas.
- DLK1 represents a promising therapeutic target for sarcoma treatment.
Related Concept Videos
02:23Abnormal Proliferation
5.0K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
5.0K
02:57Targeted Cancer Therapies
8.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.5K
01:24Regulation of Angiogenesis and Blood Supply
3.2K
Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits. Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...
3.2K
01:27Transducer Mechanism: Enzyme-Linked Receptors
3.6K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
3.6K